This study will consist of a screening period, a single residential period of 10 days/9 nights and a safety follow up period. Subjects will be randomized to either ASP2713 or placebo.
The purpose of this study is to evaluate safety and tolerability of ASP2713 in healthy participants. The study will also evaluate the pharmacokinetics and pharmacodynamics of ASP2713.